Logo image of 1REGN.MI

REGENERON PHARMACEUTICALS (1REGN.MI) Stock Fundamental Analysis

BIT:1REGN - Euronext Milan - US75886F1075 - Common Stock - Currency: EUR

487.4  +0.1 (+0.02%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to 1REGN. 1REGN was compared to 73 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1REGN a very profitable company, without any liquidiy or solvency issues. 1REGN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make 1REGN a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

1REGN had positive earnings in the past year.
1REGN had a positive operating cash flow in the past year.
In the past 5 years 1REGN has always been profitable.
In the past 5 years 1REGN always reported a positive cash flow from operatings.
1REGN.MI Yearly Net Income VS EBIT VS OCF VS FCF1REGN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

Looking at the Return On Assets, with a value of 11.67%, 1REGN belongs to the top of the industry, outperforming 91.78% of the companies in the same industry.
1REGN has a better Return On Equity (14.89%) than 86.30% of its industry peers.
With an excellent Return On Invested Capital value of 8.81%, 1REGN belongs to the best of the industry, outperforming 86.30% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1REGN is in line with the industry average of 11.99%.
Industry RankSector Rank
ROA 11.67%
ROE 14.89%
ROIC 8.81%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.56%
ROIC(5y)16.89%
1REGN.MI Yearly ROA, ROE, ROIC1REGN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

With an excellent Profit Margin value of 31.37%, 1REGN belongs to the best of the industry, outperforming 91.78% of the companies in the same industry.
In the last couple of years the Profit Margin of 1REGN has grown nicely.
Looking at the Operating Margin, with a value of 28.56%, 1REGN belongs to the top of the industry, outperforming 89.04% of the companies in the same industry.
1REGN's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 86.46%, 1REGN belongs to the top of the industry, outperforming 82.19% of the companies in the same industry.
1REGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.56%
PM (TTM) 31.37%
GM 86.46%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
1REGN.MI Yearly Profit, Operating, Gross Margins1REGN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1REGN is still creating some value.
The number of shares outstanding for 1REGN remains at a similar level compared to 1 year ago.
The number of shares outstanding for 1REGN has been reduced compared to 5 years ago.
The debt/assets ratio for 1REGN has been reduced compared to a year ago.
1REGN.MI Yearly Shares Outstanding1REGN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
1REGN.MI Yearly Total Debt VS Total Assets1REGN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

1REGN has an Altman-Z score of 6.81. This indicates that 1REGN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.81, 1REGN belongs to the top of the industry, outperforming 86.30% of the companies in the same industry.
1REGN has a debt to FCF ratio of 0.76. This is a very positive value and a sign of high solvency as it would only need 0.76 years to pay back of all of its debts.
1REGN's Debt to FCF ratio of 0.76 is amongst the best of the industry. 1REGN outperforms 97.26% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1REGN is not too dependend on debt financing.
1REGN has a better Debt to Equity ratio (0.09) than 65.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.76
Altman-Z 6.81
ROIC/WACC0.81
WACC10.91%
1REGN.MI Yearly LT Debt VS Equity VS FCF1REGN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

A Current Ratio of 4.60 indicates that 1REGN has no problem at all paying its short term obligations.
The Current ratio of 1REGN (4.60) is better than 76.71% of its industry peers.
A Quick Ratio of 3.93 indicates that 1REGN has no problem at all paying its short term obligations.
The Quick ratio of 1REGN (3.93) is better than 75.34% of its industry peers.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 3.93
1REGN.MI Yearly Current Assets VS Current Liabilites1REGN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.42% over the past year.
Measured over the past years, 1REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
Looking at the last year, 1REGN shows a small growth in Revenue. The Revenue has grown by 5.38% in the last year.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)2.42%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%11.51%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%3.62%

3.2 Future

Based on estimates for the next years, 1REGN will show a small growth in Earnings Per Share. The EPS will grow by 5.56% on average per year.
1REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.44% yearly.
EPS Next Y-20.91%
EPS Next 2Y-6.05%
EPS Next 3Y2.71%
EPS Next 5Y5.56%
Revenue Next Year-5.41%
Revenue Next 2Y0.44%
Revenue Next 3Y3.74%
Revenue Next 5Y4.44%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1REGN.MI Yearly Revenue VS Estimates1REGN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B
1REGN.MI Yearly EPS VS Estimates1REGN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 12.44, 1REGN is valued correctly.
Based on the Price/Earnings ratio, 1REGN is valued cheaper than 90.41% of the companies in the same industry.
1REGN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.48.
1REGN is valuated correctly with a Price/Forward Earnings ratio of 14.09.
Based on the Price/Forward Earnings ratio, 1REGN is valued cheaply inside the industry as 90.41% of the companies are valued more expensively.
1REGN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.04.
Industry RankSector Rank
PE 12.44
Fwd PE 14.09
1REGN.MI Price Earnings VS Forward Price Earnings1REGN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1REGN is valued cheaper than 84.93% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1REGN indicates a rather cheap valuation: 1REGN is cheaper than 83.56% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 17.24
EV/EBITDA 11.17
1REGN.MI Per share data1REGN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200

4.3 Compensation for Growth

The excellent profitability rating of 1REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.95
EPS Next 2Y-6.05%
EPS Next 3Y2.71%

More info and screens

2

5. Dividend

5.1 Amount

With a yearly dividend of 0.63%, 1REGN is not a good candidate for dividend investing.
1REGN's Dividend Yield is rather good when compared to the industry average which is at 12.94. 1REGN pays more dividend than 93.15% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.39, 1REGN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.63%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y-6.05%
EPS Next 3Y2.71%
1REGN.MI Yearly Income VS Free CF VS Dividend1REGN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

REGENERON PHARMACEUTICALS

BIT:1REGN (7/28/2025, 7:00:00 PM)

487.4

+0.1 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners91.91%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap52.62B
Analysts80
Price Target638.34 (30.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.63%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.56%
Min EPS beat(2)-8.66%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)12.63%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)8.06%
EPS beat(12)10
Avg EPS beat(12)9%
EPS beat(16)13
Avg EPS beat(16)9.97%
Revenue beat(2)1
Avg Revenue beat(2)0.2%
Min Revenue beat(2)-9.31%
Max Revenue beat(2)9.72%
Revenue beat(4)1
Avg Revenue beat(4)-0.28%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)8
Avg Revenue beat(12)1.29%
Revenue beat(16)12
Avg Revenue beat(16)3.14%
PT rev (1m)-2.03%
PT rev (3m)-34.64%
EPS NQ rev (1m)0.27%
EPS NQ rev (3m)-19.16%
EPS NY rev (1m)-0.51%
EPS NY rev (3m)-16.91%
Revenue NQ rev (1m)2.19%
Revenue NQ rev (3m)-5.58%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-8.59%
Valuation
Industry RankSector Rank
PE 12.44
Fwd PE 14.09
P/S 4.31
P/FCF 17.24
P/OCF 12.92
P/B 2.05
P/tB 2.14
EV/EBITDA 11.17
EPS(TTM)39.18
EY8.04%
EPS(NY)34.58
Fwd EY7.1%
FCF(TTM)28.28
FCFY5.8%
OCF(TTM)37.72
OCFY7.74%
SpS113.02
BVpS238.06
TBVpS227.31
PEG (NY)N/A
PEG (5Y)0.95
Profitability
Industry RankSector Rank
ROA 11.67%
ROE 14.89%
ROCE 11.75%
ROIC 8.81%
ROICexc 11.24%
ROICexgc 11.83%
OM 28.56%
PM (TTM) 31.37%
GM 86.46%
FCFM 25.02%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.56%
ROIC(5y)16.89%
ROICexc(3y)38.5%
ROICexc(5y)36.52%
ROICexgc(3y)45.41%
ROICexgc(5y)40.67%
ROCE(3y)15.42%
ROCE(5y)22.52%
ROICexcg growth 3Y-3.25%
ROICexcg growth 5Y17.1%
ROICexc growth 3Y-7.38%
ROICexc growth 5Y14.08%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.76
Debt/EBITDA 0.59
Cap/Depr 232.74%
Cap/Sales 8.35%
Interest Coverage 250
Cash Conversion 103.81%
Profit Quality 79.76%
Current Ratio 4.6
Quick Ratio 3.93
Altman-Z 6.81
F-Score5
WACC10.91%
ROIC/WACC0.81
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.77%
Profit Quality(5y)77.84%
High Growth Momentum
Growth
EPS 1Y (TTM)2.42%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%11.51%
EPS Next Y-20.91%
EPS Next 2Y-6.05%
EPS Next 3Y2.71%
EPS Next 5Y5.56%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%3.62%
Revenue Next Year-5.41%
Revenue Next 2Y0.44%
Revenue Next 3Y3.74%
Revenue Next 5Y4.44%
EBIT growth 1Y-2.61%
EBIT growth 3Y-22.17%
EBIT growth 5Y13.8%
EBIT Next Year-14.3%
EBIT Next 3Y4.69%
EBIT Next 5Y6.01%
FCF growth 1Y18.37%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y0.1%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%